Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
Hansa Biopharma (NASDAQ Stockholm: HNSA) has appointed Dr. Richard Philipson as Chief Medical Officer (CMO), effective July 14, 2025. Dr. Philipson brings over 25 years of industry experience and will report to CEO Ren茅e Aguiar-Lucander as a member of the Executive Committee.
Dr. Philipson's extensive background includes serving as CMO at Calliditas Therapeutics, 16 years at GlaxoSmithKline including leadership in the Rare Diseases Unit, and positions at Takeda and Trizell. His track record includes contributing to four product approvals in rare disease and gene therapy, along with expertise in building clinical development programs across all phases.
- Appointment of highly experienced CMO with 25+ years of industry expertise
- New CMO brings track record of 4 successful product approvals
- Extensive experience in rare diseases and gene therapy development
- Strong background in regulatory strategy and clinical development across all phases
- None.
Dr Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across all phases of development.听 He also brings in-depth knowledge of regulatory strategy in drug development. Dr Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year period as CMO at Trizell.听
"We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development," said CEO Ren茅e Aguiar-Lucander.
"I am excited to have the opportunity to join Hansa at this stage of the company's development. I look forward to working with the Hansa team and leveraging my experience from prior roles to support upcoming regulatory submissions and help build a strategic development plan for future indications," said Dr Philipson.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
[email protected]
Stephanie Kenney, VP Global Corporate Affairs
[email protected]
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in
漏2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision
The following files are available for download:
| 20250708-CMO_ENG_FINAL |
听
View original content:
SOURCE Hansa Biopharma AB
FAQ
Who is the new Chief Medical Officer of Hansa Biopharma (HNSA)?
What is Dr. Richard Philipson's experience before joining Hansa Biopharma (HNSA)?
When will Dr. Philipson start his role as CMO at Hansa Biopharma?
What will be Dr. Philipson's responsibilities at Hansa Biopharma (HNSA)?
